Which adverse effect is noted with evinacumab therapy?

Enhance your knowledge of antihyperlipidemics and lipid management. Study with multiple choice questions and detailed explanations. Ace your test!

Evinacumab, a monoclonal antibody against ANGPTL3 used for homozygous familial hypercholesterolemia, is most consistently associated with nasopharyngitis in clinical trials. This reflects a tendency for mild upper respiratory infections to appear with many antibody therapies due to systemic exposure and immune interactions. While rash, muscle ache, or tremor can occur, they are not as commonly reported with evinacumab as nasopharyngitis.